The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| NBIX | +21.12% | +54.38% | +9.07% | +1,120% |
| S&P | +12.94% | +86.25% | +13.25% | +910% |
Neurocrine Biosciences discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $794.90M | 27.8% |
| Gross Profit | $780.90M | 28.3% |
| Gross Margin | 98.24% | 0.4% |
| Market Cap | $13.92B | 19.7% |
| Market Cap / Employee | $7.74M | 0.0% |
| Employees | 1.8K | 28.6% |
| Net Income | $209.50M | 61.4% |
| EBITDA | $247.00M | 29.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $340.20M | -2.5% |
| Accounts Receivable | $728.00M | 51.3% |
| Inventory | 69.3 | 51.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $428.40M | 70.4% |
| Short Term Debt | $51.30M | 47.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 10.97% | -1.1% |
| Return On Invested Capital | 12.25% | 1.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $214.30M | 43.0% |
| Operating Free Cash Flow | $227.50M | 44.0% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 41.48 | 37.50 | 37.10 | 33.53 | 8.61% |
| Price to Book | 5.08 | 4.25 | 4.91 | 5.16 | 20.28% |
| Price to Sales | 5.96 | 4.70 | 5.06 | 5.36 | 0.10% |
| Price to Tangible Book Value | 5.16 | 4.31 | 4.98 | 5.23 | 20.14% |
| Price to Free Cash Flow TTM | 25.21 | 23.03 | 24.01 | 24.26 | -11.15% |
| Enterprise Value to EBITDA | 88.53 | 347.80 | 79.85 | 55.68 | -3.82% |
| Free Cash Flow Yield | 4.0% | 4.3% | 4.2% | 4.1% | 12.55% |
| Return on Equity | 14.2% | 12.4% | 13.4% | 15.0% | -8.50% |
| Total Debt | $495.70M | $493.10M | $489.80M | $479.70M | 67.61% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
